| JCI |
Report |
Adjusted EPS |
BEAT |
pred ~$1.33 vs. cons $1.301 |
MEDIUM |
| JCI |
Report |
Operating sales |
BEAT |
pred ~$6.52B vs. cons $6.451B |
MEDIUM |
| JCI |
Report |
Operating EBITA margin |
IN-LINE |
pred ~18.9% vs. cons 18.77% |
MEDIUM |
| JCI |
Guide |
FY2026 adjusted EPS |
UNCHANGED |
guide ~$4.95 vs. cons $4.903 |
MEDIUM |
| JCI |
Guide |
FY2026 Q4 adjusted EPS |
UNCHANGED |
guide ~$1.54 vs. cons $1.525 |
MEDIUM |
| JCI |
Guide |
FY2026 organic growth |
BETTER |
guide ~7% vs. cons UNVERIFIED |
LOW |
| JCI |
Guide |
Orders / backlog conversion |
BETTER |
guide: accelerating conversion; orders above algorithm vs. cons UNVERIFIED |
LOW |
| JCI |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.5% |
— |
MEDIUM |
| JCI |
Return |
5-day cumulative residual |
+4.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — raise supports revisions |
MEDIUM |